Navigation Links
Orexigen® Therapeutics Schedules August 5, 2010 Webcast Discussion of Financial Results for the Second Quarter Ended June 30, 2010
Date:7/29/2010

SAN DIEGO, July 29 /PRNewswire-FirstCall/ -- Orexigen® Therapeutics, Inc. (Nasdaq: OREX), a biopharmaceutical company focused on the treatment of obesity, will announce its second quarter ended June 30, 2010 financial results on Thursday, August 5, 2010 after the markets close. The announcement will be followed by a live webcast and conference call at 5:00 p.m. Eastern time.

Orexigen management will host the call and webcast to discuss financial results and recent business highlights. The live call may be accessed by phone by calling (800) 901-5248 (domestic) or (617) 786-4512 (international), participant code 86709407. The webcast can be accessed live on the investor relations section of the Orexigen web site at www.orexigen.com  and will be archived for 14 days following the call.

About Orexigen Therapeutics

Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the treatment of obesity. The Company has filed an NDA with the FDA for its lead investigational product, Contrave®. The Company's second product, Empatic™, has completed Phase 2 clinical development.  Each product candidate is designed to act on a specific group of neurons in the central nervous system with the goal of achieving appetite suppression and sustained weight loss, through combination therapeutic approaches. Further information about the Company can be found at http://www.Orexigen.com.


'/>"/>
SOURCE Orexigen Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Orexigen® Therapeutics Announces FDA Acceptance of Contrave® New Drug Application for the Treatment of Obesity
2. Amicus Therapeutics to Host Its Second Quarter 2010 Financial Results Conference Call and Webcast on August 5, 2010
3. Abviva Announces Notice of Canadian Patent for Technology Used in Breast Cancer Diagnostics and Therapeutics
4. MabVax Therapeutics Initiates Phase II Clinical Trial of Vaccine to Prevent Recurrent Sarcoma
5. Cornerstone Therapeutics to Host Second Quarter 2010 Conference Call
6. Richard B. Brewer Joins Nile Therapeutics as Executive Chairman of the Board of Directors
7. Cara Therapeutics Secures $15 Million Series D Financing to Continue Clinical Development of CR845
8. Arcion Therapeutics Topical Gel Candidate, ARC-4558, Demonstrates Significant Pain Reduction in Phase 2b Trial for Painful Diabetic Neuropathy (PDN)
9. Elusys Therapeutics and Lonza Extend Manufacturing Agreement for Anthim, a New Anthrax Treatment in Late-Stage Development
10. Silence Therapeutics and AstraZeneca Extend siRNA Development Collaboration
11. Nile Therapeutics Completes Dosing of Phase II Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... -- LexisNexis® Risk Solutions, a leading provider of data, ... LexisNexis Provider Performance Monitor , a clinical ... the quality and efficiency of provider networks through ... measuring provider performance through Provider Performance Monitor, payers ... improve the patient experience and reduce costs, as ...
(Date:2/10/2016)... 2016 Mast Therapeutics, Inc. (NYSE ... for sickle cell disease and heart failure, today announced ... units at a price to the public of $0.275 ... the Company,s common stock and one warrant to purchase ... exercise price of $0.42 per share. The warrants are ...
(Date:2/10/2016)... 10, 2016 ALSP, Inc. announced that it has ... for Medical Affairs in preparation for its move into clinical ... PhD, CEO, stated, "We are pleased to welcome Dallas ... working with an individual of such practical knowledge and far-reaching ... drawing deeply on his broad experience and success as a ...
Breaking Medicine Technology:
(Date:2/10/2016)... ... 10, 2016 , ... Gout is like no other joint pain. It strikes ... with intense swelling and redness. It is triggered by the crystallization of uric acid ... the most susceptible, according to the February 2016 issue of Harvard Men's Health Watch. ...
(Date:2/10/2016)... ... 10, 2016 , ... AHRA: The Association for Medical Imaging ... Fox will serve as keynote speaker at the organization’s 2016 Spring Conference. Fox’s ... more effectively communicate with their own organizational staff and leadership. , “I ...
(Date:2/10/2016)... MN (PRWEB) , ... February 10, 2016 , ... ... that it will attend the Ohio Safety Congress and Expo event March 9-11, ... at the Greater Columbus Convention Center. , As the longest running and ...
(Date:2/10/2016)... (PRWEB) , ... February 10, 2016 , ... ... revolutionary, biocompatible columns and accessories. These PEEK-lined stainless steel (PLS) columns combine the ... a solution that ensures the integrity of biological samples while operating at ultra-high ...
(Date:2/10/2016)... , ... February 10, 2016 , ... Workrite Ergonomics, who ... that has evolved from humble beginnings to being an internationally recognized leader in their ... we are today”, said Charlie Lawrence, President of Workrite. “Workrite recognized the importance ...
Breaking Medicine News(10 mins):